Navigation Links
Quest Diagnostics Commences Tender Offer for Acquisition of Celera
Date:3/28/2011

MADISON, N.J., March 28, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today it has commenced a tender offer through its wholly owned subsidiary, Spark Acquisition Corporation, for all of the outstanding shares of common stock (the "Shares") of Celera Corporation (Nasdaq: CRA), one of the world's pioneers in genetic diagnostics discovery and development for $8.00 per share in cash, without interest and less any required withholding taxes.

The tender offer is being made pursuant to an Offer to Purchase, dated March 28, 2011, and in connection with the previously announced Agreement and Plan of Merger, dated March 17, 2011, by and among Quest Diagnostics, Spark Acquisition Corporation and Celera.

The tender offer will expire on April 25, 2011, at 5:00 p.m. New York City time, unless extended in accordance with the Merger Agreement and the applicable rules and regulations of the Securities and Exchange Commission.  Any extension of the tender offer will be followed as promptly as practicable by public announcement thereof, and such announcement will be made no later than 9:00 a.m. New York City time on the next business day after the previously scheduled expiration date.

The tender offer is subject to customary conditions, including the tender of a majority of the outstanding Shares (calculated on a fully-diluted basis), as well as the receipt of certain regulatory approvals and other closing conditions.  The board of directors of each of Quest Diagnostics and Celera have approved the transaction.

Today, Quest Diagnostics will file with the SEC a tender offer statement on Schedule TO, setting forth in detail the terms of the tender offer.  Celera will file today with the SEC a solicitation/recommendation statement on Schedule 14D-9 setting forth in detail, among other things, the recommendation of Celera's board of directors that Celera stockholders accept the tender offer and tender their Shares pursuant to the offer.

The Depositary for the tender offer is Computershare Trust Company, N.A.  The Information Agent for the tender offer is D.F. King & Co., Inc.  The Dealer Manager for the tender offer is Morgan Stanley & Co. Incorporated.  The tender offer materials may be obtained at no charge by downloading them from the SEC's website at http://www.sec.gov.  In addition, a copy of the offer to purchase, letter of transmittal and certain related tender offer documents may be obtained free of charge by directing a request to Quest Diagnostics at 973-520-2900.  A copy of the tender offer statement and Celera's solicitation/recommendation statement on Schedule 14D-9 will be made available to all stockholders of Celera free of charge at http://www.celera.com.

ABOUT QUEST DIAGNOSTICS:Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions.  Quest Diagnostics offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff.  Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. More information is available at: http://www.QuestDiagnostics.com.

LEGAL NOTICES AND DISCLAIMERS:This release is for informational purposes only.  It does not constitute an offer to purchase shares of Celera or a solicitation/recommendation under the rules and regulations of the SEC.  Quest Diagnostics is filing with the SEC a Tender Offer Statement on Schedule TO and Celera is filing a Solicitation/Recommendation Statement on Schedule 14D-9.  These documents contain important information and shareholders of Celera are advised to carefully read these documents before making any decision with respect to the cash tender offer.  These documents will be available at no charge on the SEC's website at http://www.sec.gov.  In addition, a copy of the offer to purchase, letter of transmittal and certain related tender offer documents may be obtained free of charge by directing a request to Quest Diagnostics at 973-520-2900.  A copy of the tender offer statement and Celera's solicitation/recommendation statement on Schedule 14D-9 will be made available to all stockholders of Celera free of charge at http://www.celera.com. CONTACTS:Investor related questions, via the Information Agent for the tender offer:D.F. King & Co., Inc.

Banks and Brokers:  212-269-5550Stockholders and All Others:  1-800-347-4250For Quest Diagnostics: Kathleen Valentine (Investors), +1-973-520-2900, or Wendy Bost (Media), +1-973-520-2800
'/>"/>

SOURCE Quest Diagnostics Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SimQuest Develops Worlds First Platform for Open Surgical Simulation
2. Quest Diagnostics Launches National Electronic Health Records Awareness Tour Showcasing Care360 EHR
3. Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
4. Quest Diagnostics to Acquire Celera, Strengthening Position as Worlds Leading Innovator in Molecular Diagnostics and Development
5. Questcor Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference
6. CardioGenics Requests Stockholders to Participate in Stockholder Questionnaires
7. Questcor Pharmaceuticals Selects BDO USA as its Auditor
8. Questcor Reports 2010 Financial Results
9. Physicians Who Treat Obesity Question FDA Rejection of Contrave
10. Questcor to Report Fourth Quarter and Full Year 2010 Earnings and Conduct Conference Call on February 23, 2011
11. Quest Diagnostics Announces Pricing in Offering of Common Stock by the Companys Largest Shareholder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Bay Area Lyme Foundation , collaborating ... for Tick Borne Illness , Harvard Medical School ... Medicine, University of California, Berkeley, and the Veterans ... finalists of Lyme Innovation , the first ... scientists, clinicians, researchers, entrepreneurs, and investors from several ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com recently ... of Eyeglasses . , Millions of individuals in the United States and Canada ... become a way to both correct vision and make a fashion statement. Even celebrities ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, ... Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility ... home to some of the world’s leading providers of cereal and other breakfast foods. ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
Breaking Medicine News(10 mins):